

China's IP in foreign eyes

The cooperation between China and Brazil in the technology space is progressing. Despite the recent announcements, there used to be a lot more excitement about partnerships between China and Brazil in technology.

中国和巴西之间在技术领域的合作进展迅速。据了解,两国除了近期公布的合作项目外,一直以来就有许多令人兴奋的技术合作。

Comments:

Brazil has aggressively courted Chinese manufacturers, cutting federal and state taxes on the production of tablet computers, since it has eyed that the cooperation between the two leading developing countries will make a big change to themselves and the rest of the world.

点评:

巴西一直在积极拉拢中国制造商,例如以削减联邦和各州的税收来促进平板电脑的生产。因为巴西早已看到,这两大发展中国家之间的技术合作必将给双方及全球带来巨大的变化。



Around the world online video is becoming a bigger and more sophisticated business. China's online-video market is the largest and most innovative in the world. It is also the most competitive.

网络视频业务正在世界范围内变得越来越大和复杂,在中国尤其如此。中国正成为全球最大、最具创新性的,同时也是最有竞争力的网络视频市场。

Comments:

Local companies, including Youku, Tudou and Sohu, are wildly popular in China. The size and innovation of the Chinese online-video industry is unique. However, they face the same problems.

点评:

中国本土网络视频公司,如优酷、土豆和搜狐,正受到越来越多网民的欢迎。中国网络视频行业的规模和创新能力独一无二,但在市场运作上却面临共同的问题。

(by Correspondent Wang Weiwei from Canada) (本报通讯员王玮玮发自加拿大)

Shanghai Fosun Pharmaceutical Group's subsidiary sells IPRs to SELLAS cause concern

预计 3.88 亿欧元向国外公司转让两化合物的知识产权

复星医药:收获亿元大单引发关注



As always, people generally think the innovation and R&D capacity of Chinese Pharmaceutical industry is weak, and the commonly used cardiovascular drugs, diabetes drugs and anti-cancer drugs are firmly occupied by Pfizer and Bayer.

Fochon signs agreement with SELLAS

The contract is signed between Shanghai Fosun's subsidiary Chongqing Fochon Pharmaceutical Company (Chongqing Fochon) and SELLAS Clinicals Holding AG (SELLAS). Fochon emphasized on the discovery of effective treatments for cancer and metabolic diseases.

Based on the agreement, Chongqing Fochon will transfer its global rights, except the People's Republic of China, in development, sales and distribution in two innovative therapies for Type II Diabetes and Tumor, Fotagliptin benzoate and Pan-HER Inhibitors, respectively.

"Fosun Pharma cooperates with Greek pharmaceutical R&D Company and promotes the innovative products to mainstream European and American innovative drug company. This means that the R&D investment of Fosun Pharma is entering into the harvest stage gradually.

We firmly believe that our commitment to innovation investment will continuously improve the company's innovation ability and bring in new products to markets," said Chen Qiyu, Chairman of Fosun Pharma.

The agreement caused a huge storm in the industry after it was announced to the public. As a result of this very positive news, the stock price of Fosun Pharma show up fully, but fueled the suspicion and controversy over the transaction behavior as well.

"The pharmaceutical licenced by Fosun Pharma, however, are under pre-clinical phases, while most of pharmaceutical would be eliminated in that phase, that is to say, it is unclear whether the total contract amount could be honored."

Explores mature trade mode

Fosun Pharma's success is far from guaranteed. But it is a critical question worth our profound meditation. For many years, the problems faced by domestic pharmaceutical company including weak innovation capacity, unreasonable industry structure, low S&T industry arrangement and substandard market operation order.

With biology and pharmaceutical industry classified as new strategy industry, China has attached a great importance to the industry. The domestic biology and pharmaceutical industry is on the rise, narrowing the gap between it and developed countries.

Some group of biology and pharmaceutical projects with high market reputation and good market prospects are extremely popular with overseas pharmaceutical companies. How to promote the Chinese pharmaceutical company to go overseas? The relevant expert suggest that China must keep improving self-innovation and pharmaceutical R&D, and explore a high-quality and systematic achievement transformation model, thus gradually integrated pharmaceutical development and market demand.

"In recent years, China has indeed increased its innovation strength in pharmaceutical industry, and the export of pharmaceutical technology shown a tendency to increase, but not on a large scale. The main problems are: firstly, compared with huge spending on R&D of new pharmaceutical, the investment of Chinese new pharmaceutical is quite limited, while Chinese capital market (including angel investment and venture investment) is not yet ready for developing new pharmaceutical.

本报记者 王康

一直以来,中国医药企业创新能力较弱,研发实力欠缺是留给公众的普遍印象,市场上老百姓常患的心血管、糖尿病、抗凝类药物也几乎被美国辉瑞、德国拜耳等国外公司牢牢占据。

费用的消息不胫而走,频见报端,引发产业界关注。

复星收获亿元大单

据了解,此次交易为复星医药控股子公司重庆复创医药研究有限公司(下称重庆复创)与一家名为 SELLAS Clinicals Holding AG (以下简称 SELLAS 公司)的医药公司间的合作。

按照双方约定,重庆复创将向 SELLAS 公司转让其独立研究开发的涉及针对 II 型糖尿病和肿瘤的二种化合物全球范围(除中国市场)的开发、销售等权利,转让价格预计约为 3.88 亿欧元(约合人民币 32.48 亿元)。

此外,复星医药在协议中保留了两种化合物在中国区的收益权和欧美地区部分收益权。复星医药董事长陈启宇在接受中国知识产权报记者采访时表示,此次合作是复星医药将创新成果推向欧美主流创新药企业的探索,这意味着复星医药多年的研发投入逐步进入收获期,并坚信在不断的投入下,复星医药的创新能力会得到持续提升,创新成果会不断涌现。

复星医药的巨额转让协议对外公布后,随即在业内引发巨大反响。受到此利好消息的影响,复星医药的股价随即出现一轮明显上涨,但同时也加剧了市场对此交易行为的质疑和争议。

模式等方面都存在诸多疑点。

一位有着多年医药专利运营经验但不愿透露姓名的人士在接受本报记者采访时也对此次交易的诸多疑点提出了自己的观点。

探索成熟交易模式

复星医药的此次转让行为能否成功,我们现在还不得而知,但其背后所反映出来的深层次的问题值得我们深思:一直以来,国内医药企业自主创新能力弱、产业结构不合理、科技成果转化率低、市场环境有待规范等问题较为突出。

随着国家将生物医药产业列为战略性新兴产业给予重点支持和培育,国内生物医药产业发展迅猛,与国外发达国家的差距正在缩小,中国生物医药产业已经进入依托科技自主创新、转变增长模式的重要战略转折期,一批市场前景好的生物医药项目开始受到国际医药企业的青睐和注意。

"近年来,中国医药产业创新实力的确有显著提高,中国向海外输出新药技术的案例逐渐增多,但尚不成规模,存在的主要问题是:与新药研发所需的巨额投入相比,中国对新药研发的投入仍然偏低,而且我们的资本市场(包括天使投资、风险投资等)尚未形成对新药研发强大的支撑;高水平研发人才的短缺也是制约中国新药研发能力提升的重要瓶颈因素。"

IP Brief

Beijing

Recently, the eighth China Beijing International Cultural & Creative Industry Expo (ICCCIE) concluded. The theme of the Expo is promoting culture trade and facilitating economic upgring.

According to incomplete statistics, some letters of intent encompassing creative product trade, park construction, project investment and cooperation between bank and company and were signed, inking 119.036 billion Yuan.


北京

日前,第八届中国北京国际文化创意产业博览会在北京落幕。此次博览会以"促进文化贸易,加快经济升级"为主题。

据不完全统计,本届文博会期间,共签署文化创意产业产品交易、产业园区建设、项目投资、银企合作等协议总金额 1190.36 亿元人民币。

Jiangsu

2013 Jiangsu patent administration



tion enforcement training class hosted by SIPO and Jiangsu IP Office was held in Huaian.

The topics cover patent law, patent administration enforcement rule, basic requirement for enforcement and so on. 100 administrative personnels from three-level governments (province, city and county) took the course.

江苏

近日,由中国国家知识产权局主办,江苏省知识产权局承办的 2013 年度江苏省专利行政执法培训班在淮安市开班。

据悉,此次培训内容包括专利法、专利行政执法规程、行政执法基

本要求等,来自江苏省、市、县三级的 100 多名专利行政执法人员参加了此次培训。

Shandong

The eighth sessions of Shandong invention and venture award awarded 135 inventors, including 15 first prizes, 30 second prizes, 60 third prizes and 30 outstanding prizes.

According to the statistics, 245 elected inventors owned 2,882 patents, 773 of which are inventions.

山东

日前,第八届山东省"发明创业

奖"评选活动结果揭晓,共有 135 名发明创业者获得了奖励。其中一等奖 15 名,二等奖 30 名,三等奖 60 名,优秀奖 30 名。

据统计,此次入选的 245 名参评人员共获得专利 2882 件,其中发明专利 773 件。

Zhejiang

Recently, 977 candidates participated in 2013 national patent bar examination in Hangzhou, Zhejiang province. A total of 1,050 candidates have registered to sit the examination, up 411 over last year.

Some ten years later, Zhejiang was approved to set up examination sites again, which not only help to facilitate more and more candidates' registration, but also improve the service of patent bar in the province.

浙江

近日,2013 年全国专利代理人资格考试开考,共有 977 人在浙江省杭州市考点参加考试。今年杭州考点报名人数为 1050 人,比去年增加了 411 人。

相关负责人表示,此次浙江省时隔 10 年后重新获批设立考点,有助

于激发考生的报考热情,提升浙江省专利代理行业的服务质量。

Jiangxi

A symposium on Jiangxi IP judicial, together with IP judicial practice training was held by Jiangxi Higher People's Court recently.

At the symposium, the relevant principal of the court summarized the IP judicial work since 2010, analysed the situation and set goals for the next stage.

江西

日前,江西省高级人民法院在南昌召开全省法院知识产权审判工作座谈会,同时组织了知识产权司法实务培训。

座谈会上,江西省高级人民法院相关负责人总结了 2010 年以来全省法院知识产权审判工作,分析当前江西省法院知识产权审判面临的形势,明确下一阶段知识产权审判工作的目标任务。

英文翻译 柳鹏

Translator Liu Peng

责任编辑 陈建明

Executive Editor Chen Jianming